易布鲁替尼加RCHOP与RCHOP仅在患有激活B细胞样扩散性大B细胞淋巴瘤 (ABC-DLBCL) 的年轻患者中:成本效益分析
Hayeong Rho1, Irene Joo-Hyun Jeong1, Anca Prica1,2
1Department of Medicine, University of Toronto, Toronto, ON M5G 1V7, Canada.
Current oncology (Toronto, Ont.)
|December 22, 2023
概括
在标准RCHOP化疗 (I-RCHOP) 中添加易布鲁替尼是年轻的扩散性大B细胞淋巴瘤 (DLBCL) 患者的成本有效策略. 与单独使用RCHOP相比,这种方法改善了质量调整后的寿命年数和生存结果.
科学领域:
- 在瘤学瘤学.
- 卫生经济学 卫生经济学
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 的标准治疗方法是RCHOP (瑞图西马布,环胺,多克索鲁比辛,温克里斯,普雷尼松).
- DLBCL的ABC亚型的预后较差,需要改进治疗策略.
- 在PHOENIX试验中,建议将ibrutinib添加到RCHOP (I-RCHOP) 中,有利于年轻患者.
研究的目的:
- 为了评估I-RCHOP与RCHOP相比,ABC-DLBCL的年轻患者 (<60岁) 的成本效益.
- 为了为临床决策提供有关DLBCL治疗中新型治疗添加剂的信息.
- 在成本效益模型中分析治疗途径,不良事件,复发和生存.
主要方法:
- 使用马尔科夫决策分析模型来比较I-RCHOP和RCHOP.
- 关于救援治疗和新疗法的数据被纳入模型.
- 经过质量调整的寿命年 (QALY) 和增量成本效益比 (ICER) 的使用,评估了成本效益.
主要成果:
- 与RCHOP (14.25年) 相比,I-RCHOP表现出更大的QALY (15.48年).
- 对于I-RCHOP的ICER是CAD 34,111.45/QALY,这表明有利的成本效益.
- 敏感性分析证实了模型发现的可靠性.
结论:
- 建议I-RCHOP作为年轻的ABC-DLBCL患者首选的经济有效策略.
- 这一策略在管理不良事件,改善整体存活率和提高生活质量方面提供了好处.
- 决策分析模型提供了可靠的数据,以指导DLBCL管理中的临床实践.
关键词:
马尔科夫·马尔科夫 (Markov Markov) 是一个著名的作家.菲尼克斯 (PHOENIX) 是一个城市.这是一个RCHOP的RCHOP.对成本效益的分析.扩散大的B细胞淋巴瘤.伊布鲁丁尼布可以.更多相关视频
14:04Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
Published on: March 25, 2016
15.3K
11:29HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
11.1K
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...